High-dose pharmaceutical-grade biotin in patients with demyelinating neuropathies: a phase 2b open label, uncontrolled, pilot study

Table 8 Rheobase

	W0	W24	W48	Absolute change between W0 and W48	p-value
CIDP	13.28 (5.56;14.61)	10.28 (7.72;15.28)	4.39 (3.72;12.50)	-1.17 (-1.74;-0.78)
anti-MAG	19.44 (12.39;20.61)	7.22 (7.17; 16.83)	5.38 (4.67;11.22)	-8.22 (-9.22;-7.72)
CMT1	11.06 (7.23;12.50)	16.83 (7.28;18.39)	7.31 (7.31;10.72)	-4.21 (-5.19;-0.34)
All patients	12.50 (7.02;20.61)	10.28 (7.22;18.39)	7.31 (3.72;11.39)	-4.21 (-9.22;-0.78)	< .001

Missing data at W48 were imputed with the LOCF method (W24 for patient #04, CIDP group). The results are expressed in mA as median (IQR), in CIDP group (n = 5), anti-MAG group (n = 5), CMT1 group (n = 5) and in all patients (n = 15). The P-value was calculated with the Wilcoxon signed rank test in all patients (n = 15)

ISSN: 1471-2377